Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Synt:em other research news

Synt:em S.A., Nimes, France
Product: Pep:trans

Read the full 62 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE